Characterising Neurobiological Abnormalities In Cannabis Use Disorders
Funder
National Health and Medical Research Council
Funding Amount
$731,571.00
Summary
Severe Cannabis Use Disorders cause significant harms to quality of life and outcomes including mental health, cognition, motivation and general well being. We will characterise, for the first time, the neuroadaptations associated with cannabis dependence relative to regular use via advanced imaging techniques and examine links between neural alterations and quality of life. This study will help to identify new treatment targets and develop a new neural model of cannabis addiction.
Healthy, Wealthy And Wise: The Long-term Effectiveness Of An Online Universal Program To Prevent Substance Use And Mental Health Problems Among Australian Youth
Funder
National Health and Medical Research Council
Funding Amount
$1,472,709.00
Summary
The proposed study represents a unique opportunity to build on the NHMRC funded Climate Schools Combined (CSC) study, a world-first trial of a combined, internet-delivered school-based approach to preventing substance use, anxiety and depression. Having successfully implemented this trial and followed these students for 3 years, we propose to extend follow-up of this large trial cohort over the critical transition from secondary school into early adulthood.
Efficacy Of A 3-month Aerobic Exercise Regime For Restoring 'brain Health' In Heavy Cannabis Users
Funder
National Health and Medical Research Council
Funding Amount
$1,209,221.00
Summary
Over a ten-year period, we, and others have documented the brain and psychological harms associated with regular cannabis use. We have now shown that these harms are not permanent, but can be restored. However, the recovery process takes a long time. This study will build on our extensive work to date and, for the first time, investigate whether a specific form of exercise will cause accelerated and beneficial changes in i) the brain and ii) the daily lives of heavy cannabis users.
An RCT Of Cannabinoid Replacement Therapy (Sativex®) For The Management Of Treatment-resistant Cannabis Dependent Patients
Funder
National Health and Medical Research Council
Funding Amount
$788,133.00
Summary
This project is the first-ever outpatient RCT to test if the pharmaceutical cannabinoid Sativex can safely and cost-effectively deliver better treatment outcomes for patients seeking treatment for chronic cannabis dependence. Sativex is a mouth spray with equal parts THC and cannabidiol, and appears to have a safer pharmacological profile than illicit cannabis or synthetic THC alone. Thus Sativex may lead to lower rates of psychiatric adverse events and increased cannabis abstinence rates.